Evoke Pharma announces FDA Orange Book listing of new GIMOTI patent

Evoke Pharma announced that its recently issued U.S. patent related to GIMOTI, No. 11,813,231 is now listed in the U.S. Food and Drug Administration, FDA, publication, “Approved Drug Products with Therapeutic Equivalence Evaluations”, commonly known as the “Orange Book”. The patent titled “Nasal Formulations of Metoclopramide” covers a collection of nasal solutions of metoclopramide and its characteristics when formulated. This new patent is now listed in the FDA’s Orange Book and carries a patent term to 2029. The listing of the patent in the Orange Book adds additional patent protection for GIMOTI beyond the prior three listed patents. “Due to our relentless efforts to continuously realize the significant commercial potential of GIMOTI and the need for an improved treatment solution for diabetic gastroparesis, our IP portfolio now boasts an impressive set of patents and four FDA Orange Book listings,” commented Matt D’Onofrio, President and Chief Operating Officer of Evoke Pharma. “We are proud to have achieved this milestone as we aim to redefine the standard for gastroparesis treatment by providing GIMOTI, a direct route to deliver medication leading to less hospitalizations than oral metoclopramide.”